List view / Grid view
Academia and pharma have always been uneasy bedfellows. There has in the past been tension between both caused by a range of issues that neither party was willing to try and resolve. However, there is a new impetus to solve these issues as both parties have started to realise that…
From the beginning of time in the drug discovery world, the integration of disciplines has driven the identification of new lead molecules. Chemists, pharmacologists and biologists work together to understand a disease state and how to perturb that state back towards a normal healthy condition. However, in the early days…
Monoclonal antibodies have come of age as therapeutics; there are now more than 30 antibodies on the market and over 200 in clinical trials. The attractions of therapeutic antibodies lie not only in their potential to make potent drugs but also their relative low risk in comparison to small molecule…
Protein kinases, a diverse group of cellular enzymes, play fundamental roles in maintaining normal cellular functions such as growth, cell cycle control, proliferation, differentiation, migration, cellular survival and apoptotic induction.
Immune checkpoint inhibitory antibodies have provided a great conceptual change in the field of immune-oncology. Rather than targeting the tumour directly, these novel drugs are aimed at preventing the interactions between the tumour and the immune system, which the cancer exploits to evade immune recognition...
Autophagy is a cellular homeostatic process regulating protein turnover as well as eliciting a stress response to starvation, chemical agents and pathogen infection. It has been implicated in the initiation and progression of several diseases, including neuro-degenerative disorders, Crohn’s disease, infections and cancer...
Medicine and life sciences research are being revolutionised by major technological developments that have taken place over the past decade. High-throughput sequencers can now generate high-quality nucleotide sequence data at a small fraction of the cost compared to only a few years back...
9 April 2015 | By J.R. Costa, J. Heintze, R. Ketteler, K. Papenfuss, C. Richards, S. Nahnsen, N. Graffman, P. Matz, W.Wruck, J. Adjaye, C. Williams, W. Fecke.
In this issue: Next-Generation Sequencing, Drug Targets, High Throughput Screening, Phenotypic Screening, Stem cells, Label-Free technologies and Assays...
9 April 2015 | By Caroline Richards, Editor, Drug Target Review
In this NGS In-Depth Focus; How next-generation sequencing came to be, plus a brief history & Data management for large-scale NGS-based research projects...
9 April 2015 | By J.R.Costa, J.Heintze, R.Ketteler, S. Gul, Dr. T.Duensing, K.Papenfuss.
In this Drug Targets In-Depth Focus, we delve into the role of a key complex required for autophagosome maturation, the ATG4-ATG8 conjugation system, and we provide insight on some up-and-coming immune checkpoint inhibitors that are currently in clinical and preclinical development...
Tim Hammonds from Cancer Research Technology Discoveries explains how academic HTS laboratories came into being and outlines the challenges facing the new HTS model...
Wolfgang Fecke and Christine Williams from UCB discuss the industry’s approach to drug discovery with costs escalating and output failing to achieve the corresponding increases in revenue...
In his fascinating overview of label-free analysis, Dr. Masson introduces the four main label-free methods: physical, electrochemical, mass-based and optical techniques, before providing the reader with in-depth insight into the most common label-free technique within the pharmaceutical industry: surface plasmon resonance (SPR)...
This article evaluates a GADD45a-GFP human cell assay for rapid and reliable in vitro early genotoxicity screening...
Preview of the upcoming foreword in our April issue, written by Sheraz Gul, Vice President and Head of Biology at Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Hamburg, Germany...
